Zeeuws InvesteringsFonds
  • OVER ONS
    • ZIF
    • FONDSMANAGER
  • CRITERIA
  • INVESTERINGEN
    • TOXYS
    • DOVIDEQ MEDICAL
    • INNO4LIFE
    • MAGNETIC
    • MIMETAS
    • EAGLET EYE
    • SOTERIA MEDICAL
    • ILLUXTRON
  • NIEUWS
  • VACATURES
  • CONTACT
  • ENGLISH

TOXYS AWARDED € 50.000 BY EIT HEALTH TO DEVELOP REPROTRACKER - AN IN VITRO ASSAY FOR REPRODUCTIVE TOXITY

23/9/2016

 
Foto
At 21 september Toxys was awarded a €50.000 grant for a head-start project to further develop the ReproTracker. Toxys is dedicated to develop innovative in vitro toxicity assays that provide insight into the mechanisms of toxicity. Toxys’ lead product ToxTracker is a genotoxicity assay that provides mechanistic insight into genotoxicity and is available on the market. Toxys has now applied their knowledge and expertise to validate a novel assay, ReproTracker, which provides mechanistic insight into reproductive toxicity.

​About ReproTracker
ReproTracker is an in vitro assay to visualise the key events during early embryonic development and thereby reliably assess the potential developmental toxicity hazards of new drugs and products. ReproTracker meets the strong demand from industry for better in vitro tests to predict human health hazards of their products during the early phases of product development. The assay is build on the technical and scientific background that has been developed by Toxys. We will combine our expertise on stem cell differentiation with the reporter technology that was applied in our ToxTracker assay and generate the ReproTracker reporter system that can identify developmental toxicity upon exposure to novel drugs, chemicals and materials.

​​About EIT Health

Toxys was awarded the head-start project from EIT Health, which is one of the largest healthcare initiatives worldwide. Its goal is to sustainably advance the foundations of healthcare and thus promote the future conditions for healthier living and wellbeing of people across Europe. EIT Health is leveraging the expertise of more than 130 leading organisations spanning key areas of healthcare such as Pharma, MedTech, Payers, Research Institutions and Universities. Chosen by the European Institute of Innovation and Technology (EIT) to form EIT Health, the consortium offers best-in-class research capabilities, higher education and business expertise. With a budget of 2 billion EUR over the next decade, it will purposefully invest in Europe’s best entrepreneurial talents and creative minds to foster the development and commercialisation of smart product and service solutions in the health sector, addressing the challenges imposed by demographic change and ageing societies.

Meer informatie over Toxys.

    ARCHIEF

    Maart 2020
    April 2018
    November 2017
    September 2017
    April 2017
    Januari 2017
    September 2016
    April 2016
    Maart 2016
    Februari 2016
    December 2015
    November 2015
    Oktober 2015
    September 2015
    Juli 2015
    Juni 2015
    Mei 2014
    Januari 2014
    April 2013

    ONDERNEMINGEN

    Alles
    DOVIDEQ Medical
    Eaglet Eye
    Illuxtron
    Inno4Life
    MAGnetIC
    MIMETAS
    Soteria Medical
    Toxys

 ZEEUWS INVESTERINGSFONDS
Edisonweg 41a | 4382 NV | Vlissingen | + 31 (0)6 24810367 | [email protected] | Privacy Policy